Forbes just posted this thought-provoking article written by the former President of Pfizer Global Research.  Using an approach Merck attempted as an example, he discusses some of the challenges that decision makers face these days in relation to drug safety, regulatory bodies and long-term outcomes research, and what lessons we can take away.

About a dozen years ago, a team of Merck scientists met with upper management to discuss a new approach for treating cardiovascular disease. The approach was simple, but clever. The scientists had a way of turning a well known and widely used drug, niacin, into an even better and safer drug, thereby expanding its usage.  Read More Here